Should I Buy RLMD? RLMD 2026 Analysis

Should You Buy Relmada Therapeutics Inc (RLMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.910

1 Day change

-1.01%

52 Week Range

5.120

Analysis Updated At

2026/01/26

Relmada Therapeutics Inc (RLMD) is not a strong buy at the moment given the lack of significant positive signals in technical indicators, options sentiment, and financial performance. While insider buying and analyst upgrades provide some positive sentiment, the company's financials are weak, and there is no strong immediate catalyst for growth. For a beginner investor with a long-term horizon, it's better to wait for clearer signs of improvement or stronger momentum.

Technical Analysis

The MACD is negative and contracting (-0.0574), RSI is neutral at 43.452, and moving averages are converging, indicating no clear trend. Key support is at 3.663, and resistance is at 4.381. The stock is trading below the pivot point of 4.022, suggesting limited upward momentum.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The options data shows a bullish sentiment with a low put-call ratio, but the implied volatility is high (148.08), suggesting uncertainty. No strong trading sentiment is evident.

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has increased significantly by 1133.44% in the last month, indicating confidence from insiders.
Analysts have upgraded the stock recently, with price targets of $8 and $9, citing the potential of the NDV-01 drug pipeline in oncology.
The addressable market for NDV-01 is appealing, with a potential $2.3B in non-risk-adjusted peak sales.

Neutral/Negative Catalysts

Weak financial performance in Q3 2025, with net income dropping by -53.55% YoY and EPS declining by -58.33% YoY.
Lack of recent news or event-driven catalysts to drive momentum.
Hedge funds are neutral, and there are no significant trading trends from institutional investors.

Financial Performance

The company's financials for Q3 2025 show no revenue growth (0% YoY), a significant drop in net income (-53.55% YoY), and a decline in EPS (-58.33% YoY). Gross margin remains at 0%, indicating poor financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have recently upgraded the stock to Outperform and Buy, with price targets of $8 and $9. They highlight the potential of NDV-01 in oncology and its large addressable market. However, these are long-term prospects and do not provide immediate upside.

2 Analyst Rating

Wall Street analysts forecast RLMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RLMD is 9.5 USD with a low forecast of 9 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.950

Low

Averages

9.5

High

Current: 3.950

Low

Averages

9.5

High

Leerink

Market Perform

Outperform

upgrade

AI Analysis

2026-01-23

Reason

Leerink

Price Target

AI Analysis

2026-01-23

upgrade

Market Perform

Outperform

Reason

Leerink upgraded Relmada Therapeutics to Outperform from Market Perform with an $8 price target as the analyst assumed coverage of the stock. The clinical-stage biotechnology company is focused on non- muscle invasive bladder cancer following the in-licensing of NDV-01 last March and is pursuing two development paths for NDV-01, second-line BCG-unresponsive high-risk NMIBC and adjuvant therapy following TURBT in intermediate-risk NMIBC, the analyst tells investors. The post-BCG indication represents "a competitive but well-validated regulatory entry point," while the adjuvant intermediaterisk NMIBC opportunity represents the larger long-term value driver, adds the analyst, who estimates the two indications collectively represent about $2.3B in non risk adjusted peak sales.

Jefferies

initiated

2025-12-21

Reason

Jefferies

Price Target

2025-12-21

initiated

Reason

Jefferies initiated coverage of Relmada Therapeutics with a Buy rating and $9 price target. The firm says the company has undergone a transformation in 2025, shifting from a failed central nervous system program to an oncology and neuro pipeline. The firm views Relmada's lead asset NDV-01 as "differentiated," saying it has potential as a first-line or salvage treatment across multiple bladder cancer subtypes. Jefferies views the drug's addressable market as "appealing."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RLMD

Unlock Now

RLMD Should I Buy

RLMD Should I Buy

Should You Buy Relmada Therapeutics Inc (RLMD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch